A novel compound, its preparation method, and its use in inhibiting Helicobacter pylori.
By extracting and isolating new compounds from the fruit of *Melia azedarach*, the problem of increasing drug resistance in existing antibiotic treatments for *Helicobacter pylori* has been solved, providing a potent antibacterial drug option, especially effective against drug-resistant *Helicobacter pylori*.
Patent Information
- Application Number
- CN202311518420.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-14
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-11-14
AI Technical Summary
Existing antibiotic treatments for Helicobacter pylori have led to increased drug resistance and decreased inhibition rates due to widespread use, necessitating the search for new drugs to inhibit Helicobacter pylori.
A novel compound was extracted and isolated from the fruit of *Melia azedarach*, and prepared by ethanol extraction, silica gel column chromatography, ODS column chromatography, and Sephadex LH-20 gel separation, thus revealing its inhibitory activity against *Helicobacter pylori*.
This compound exhibits stronger antibacterial activity than existing antibiotics, particularly against drug-resistant Helicobacter pylori, providing a new drug option for treating Helicobacter pylori infection.
Smart Images

Figure CN117567462B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a new compound, its preparation method, and its use in inhibiting Helicobacter pylori. Background Technology
[0002] Helicobacter pylori is a common Gram-negative microaerophilic bacterium in clinical practice, primarily found in the stomach and duodenum of individual patients. It is closely related to the development of gastric ulcers, gastritis, and gastric cancer. Currently, the most widely used clinical approach is triple therapy, which involves a proton pump inhibitor and two antibiotics. Commonly used antibiotics include metronidazole, azithromycin, clarithromycin, amoxicillin, tetracycline, and levofloxacin. However, with the widespread use of antibiotics, the development of antibiotic resistance in Helicobacter pylori has significantly increased, and the eradication rate of Helicobacter pylori is declining. Finding new drugs to inhibit Helicobacter pylori is of great importance, and obtaining compounds with inhibitory effects from natural products provides a direction for new drug development.
[0003] Evodia glabrifolia (Champ. ex Benth.) Huang, a plant belonging to the Rutaceae family, is a dried, mature fruit of the Evodia glabrifolia genus. It has the effects of warming the middle jiao and dispelling cold, promoting qi circulation and relieving pain, and is used for stomach pain, abdominal distension, and headache. Summary of the Invention
[0004] The purpose of this invention is to provide a new compound, its preparation method, and its application in the preparation of drugs that inhibit Helicobacter pylori.
[0005] The novel compound described in this invention has the following chemical structure:
[0006]
[0007] The method for preparing the novel compound of the present invention includes the following steps:
[0008] (1) Take the fruit of *Melia azedarach* and *Evodia rutaecarpa*, extract with 70% ethanol, and concentrate the extract to a relative density of 1.10 g / cm³. 3 (25℃);
[0009] (2) The concentrate was extracted with ethyl acetate, and the extract was concentrated under reduced pressure to obtain an ethyl acetate extract;
[0010] (3) The ethyl acetate extract was further separated by silica gel column chromatography. The extract was eluted with a mixture of dichloromethane and methanol at a volume ratio of 10:1. The eluent was discarded. The extract was then eluted with a mixture of dichloromethane and methanol at a volume ratio of 5:1. The eluent was collected and concentrated to extract.
[0011] (4) Dissolve the extract in methanol and then further separate it using an open ODS column. Use methanol-water (35:65) as the elution solvent, collect the eluent, and recover the solvent to obtain the crude product of the target compound.
[0012] (5) The crude product obtained in step (4) is further separated by Sephadex LH-20 gel. Methanol is used as the mobile phase. The yellow stripe eluent is collected, concentrated, and a yellow solid is obtained.
[0013] (6) Using anhydrous ethanol as the recrystallization solvent, the yellow solid obtained in step (5) is recrystallized to obtain the new compound of the present invention.
[0014] The novel compound described in this invention has inhibitory activity against Helicobacter pylori and can be used to develop drugs for treating Helicobacter pylori infection. Attached Figure Description
[0015] Figure 1 Nuclear magnetic resonance of the novel compound described in this invention 1 H-NMR spectrum
[0016] Figure 2 Nuclear magnetic resonance of the novel compound described in this invention 13 C-NMR spectrum
[0017] Figure 3 The nuclear magnetic resonance HMBC spectrum of the novel compound described in this invention.
[0018] Figure 4 The HSQC nuclear magnetic resonance spectrum of the novel compound described in this invention. Detailed Implementation
[0019] The present invention will be further described below with reference to embodiments, but these embodiments do not limit the implementation of the present invention.
[0020] Example 1
[0021] The inhibitory effect of the compound of this invention on Helicobacter pylori
[0022] 1. Materials and Methods
[0023] 1.1 Strains: Helicobacter pylori strain ATCC 43504 was purchased from American Type Culture Collection in the United States.
[0024] 1.2 Reagent: Columbia agar (Oxoid, UK)
[0025] Brain-Heart Infusion Agar (BHI-agar, BD Biosciences, USA)
[0026] Dimethyl sulfoxide (Tianjin Fuyu Fine Chemical Co., Ltd.)
[0027] 1.3 Drug Testing:
[0028] (1) Amoxicillin (130409-201512, China National Institutes for Food and Drug Control)
[0029] (2) The new compound described in this invention.
[0030] 1.4 Detection Methods
[0031] The minimum inhibitory concentration (MIC) of different reagents against Helicobacter pylori strain ATCC 43504 was determined using the agar dilution method.
[0032] (1) Preparation of culture medium: Columbia agar medium was selected, and the reagent was dissolved in dimethyl sulfoxide. Culture medium containing different drug concentrations was prepared according to the serial dilution method, so that the drug concentration in the culture medium was 128, 64, 32, ... 0.008 μg / ml.
[0033] (2) Inoculation and culture of the strain: After the strain has been revived and passaged to the second generation, freshly cultured Helicobacter pylori strains are taken and diluted with brain heart and brain extract (BHI) to a concentration of 1×10⁻⁶. 8 CFU / ml, use a micropipette to pick up 2 μl of bacterial suspension and spot it onto drug-containing agar. Use drug-free agar containing dimethyl sulfoxide as a blank control. After inoculation, place the petri dishes in a 37℃ microaerophilic (5% O2, 10% CO2, 85% N2) environment for 72 hours.
[0034] (3) Results: The lowest drug concentration on an agar plate where no colonies appear is taken as the MIC of the test drug.
[0035] Drug testing MIC (μg / ml) Amoxicillin 0.063 The new compound described in this invention 0.016
[0036] The results above show that the novel compound of this invention has a strong inhibitory effect on Helicobacter pylori, and its antibacterial effect is stronger than that of amoxicillin, the mainstream drug currently used in clinical practice. It provides a new treatment method for treating Helicobacter pylori infection, and its further development is of great significance, especially for patients who have developed drug resistance.
[0037] Example 2
[0038] Structural confirmation of the new compounds described in this invention
[0039] Yellow needle-like crystals, soluble in methanol. High-resolution mass spectrometry yielded an m / z of 417.1095 [M+H]. + The molecular ion peak (calculated value 417.1087), combined with... 1 H NMR spectrum and 13Based on the C10 NMR spectral data, the molecular formula of the compound is deduced to be C10. 23 H 16 N2O6. In 1 In the 1H NMR spectrum, δH 11.59 (1H, s) represents the nitrogen-bonded proton signal, δH 6.23, δH 6.63, δH 7.35, δH 7.43, δH 7.65, δH 7.82, δH 8.42, and δH 8.84 represent aromatic ring proton signals, and δH 3.66 in the high-field region represents the proton signal bonded to aliphatic carbons. 13 The C10 NMR spectrum yielded 20 carbon signals, of which δC 121.0 (C-4a, 4b), δC 107.5 (C-3”, 7”), and δC 146.7 (C-4”, 6”) were overlapping carbon signals, and δC 166.5 was the carboxyl carbon signal. In the HMBC spectrum, the correlation between δH 8.84 (H-4) and the signals of δC 121.0 (C-4a, 4b), δC 131.9 (C-9a), and δC 166.5 (COOH) confirmed the connection between the pyridine and indole rings in the structure, with -COOH attached at the C-3 position. The correlation between δH 7.43 (H-4') and the signal of δC 132.5 (C-1) confirmed the connection of the furan ring to C-1. The correlation between δH 6.63 (H-3') and δC 35.9 (C-1”) signals determined the connection between C-1” / C-2’ / C-3’. The correlation between δH 6.23 (H-3”, 7”) and δC 35.9 (C-1”) signals determined the connection between C-2” and C-1”. Based on the HSQC and HMBC spectra, the relevant hydrocarbon signals were assigned, as shown in Table 1. 1 The H NMR spectrum is shown in [reference]. Figure 1 , 13 The C NMR spectrum is shown below. Figure 2 HMBC spectrum can be found Figure 3 HSQC spectrum can be found Figure 4 The chemical structure of the new compound described in this invention is determined to be:
[0040]
[0041] Table 1 1 H(600MHz)and 13 C(150MHz)NMR Spectroscopic Data in DMSO(δin ppm,Jin Hz).
[0042]
[0043]
[0044] Example 3
[0045] (1) Take 10 kg of Melia toosendan fruit and extract with 10 times the amount (weight:volume) of 70% ethanol. Concentrate the extract to a relative density of 1.10 g / cm³. 3 (25℃);
[0046] (2) The concentrate was extracted four times with an equal volume of ethyl acetate. The ethyl acetate extracts were combined and concentrated under reduced pressure to obtain an ethyl acetate extract.
[0047] (3) The ethyl acetate extract was further separated by silica gel column chromatography. The ratio of extract to silica gel was 1:25 (by weight). The sample was loaded by dry method and eluted with a mixture of dichloromethane and methanol at a volume ratio of 10:1 for 5 column volumes. The eluent was discarded and then eluted with a mixture of dichloromethane and methanol at a volume ratio of 5:1 for 20 column volumes. The eluent was collected and concentrated to extract.
[0048] (4) Dissolve the extract in methanol and then further separate it using an open ODS column. The ratio of extract to ODS is 1:100 (by weight). Wet loading is performed using methanol-water (35:65) as the elution solvent. Elute for 3 column volumes, discard the eluent, and then continue eluting for 8 to 10 column volumes. Collect the eluent and recover the solvent to obtain the crude product of the target compound.
[0049] (5) The crude product obtained in step (4) is further separated by Sephadex LH-20 gel (diameter-to-height ratio of 1:100). Methanol is used as the mobile phase. The yellow stripe eluent is collected, concentrated, and a yellow solid is obtained.
[0050] (6) Using anhydrous ethanol as the recrystallization solvent, take the yellow solid obtained in step (5), add 5 times the amount (weight:volume) of anhydrous ethanol, heat until the solid dissolves, cool and then clear the yellow crystals, take the yellow crystals, and the new compound of the present invention is obtained.
Claims
1. A new compound, characterized in that, Its chemical structure is as follows: 。 2. A method for preparing the novel compound according to claim 1, characterized in that: Includes the following steps: (1) Take the fruit of Melia toosendan and extract it with 70% ethanol. Concentrate the extract to a relative density of 1.10 g / cm3 (25℃). (2) The concentrate was extracted with ethyl acetate, and the extract was concentrated under reduced pressure to obtain an ethyl acetate extract; (3) The ethyl acetate extract was further separated by silica gel column chromatography. The extract was eluted with a mixture of dichloromethane and methanol at a volume ratio of 10:
1. The eluent was discarded. The extract was then eluted with a mixture of dichloromethane and methanol at a volume ratio of 5:
1. The eluent was collected and concentrated to extract. (4) Dissolve the extract in methanol and then further separate it using an open ODS column. Use methanol-water (35:65) as the elution solvent, collect the eluent, and recover the solvent to obtain the crude product of the target compound. (5) The crude product obtained in step (4) is further separated by Sephadex LH-20 gel. Methanol is used as the mobile phase. The yellow stripe eluent is collected, concentrated, and a yellow solid is obtained. (6) Using anhydrous ethanol as the recrystallization solvent, the yellow solid obtained in step (5) is recrystallized to obtain the new compound.
3. The novel compound according to claim 1, characterized in that: The compound has inhibitory activity against Helicobacter pylori.
4. The novel compound according to claim 1, characterized in that: Used to prepare drugs that inhibit Helicobacter pylori.
Citation Information
Patent Citations
Traditional Chinese medicine for treating helicobacter pylori
CN107898887A
Novel alkaloid and application thereof in preparation of anti-helicobacter pylori drugs
CN111808119A
